News

NeurogesX has recruited around 183 patients for this trial. The Phase 2 clinical study design included two stages. The first stage was intended to establish the shortest tolerable

The new patent entitled, ‘KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME,’ covers the usage of asimadoline in treating diarrhea predominant irritable bowel syndrome (D-IBS). The

Earlier in May 2009, Takeda signed an agreement with Novartis, under which the Switzerland-based Novartis has provided license rights to market and distribute Hib vaccine TAK-816 (Vaxem Hib)

ALKS 5461 is the combination of ALKS 33 and buprenorphine. The trial will evaluate the safety, efficacy and pharmacokinetics of ALKS 5461 in 32 patients who are suffering

All the patients received injections in the lumbar region of the spine only. The trial plans to enroll up to 18 ALS patients, who are both non-ambulatory and

The inspection was done in connection with the Brazilian Ministry of Health’s investigation of the new drug application (NDA) filed with ANVISA for taliglucerase alfa to treat gaucher

Ceapro said previous collaborative work by the University of Prince Edward Island, NRC, and Agriculture and Agri-Food Canada found that a specific variety contained multiple compounds are capable

The trial willo involve around 330 patients throughout the US and Europe. The trial intends to show the overall survival benefit of IMA901 in conjunction with standard first-line

Results from this 718 patient, double-blind, placebo controlled trial were consistent with the profile observed in previous clinical studies of nalmefene. Nalmefene is a small molecule opioid receptor